Evidence map›Paper›PMID 42871872›Full record

ArticlePractical laboratory medicine2026

Identifying and resolving analytical outliers in lipoprotein(a) immunoassay testing.

Alexandria N Jackson, Sara P Wyness, Joseph W Rudolf, Jonathan R Genzen

Abstract read
In one paragraph

Article in Practical laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alexandria N JacksonARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT, 84108, USA.
Sara P WynessARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT, 84108, USA.
Joseph W RudolfUniversity of Utah Health, Department of Pathology, 15 N Medical Dr. East, Ste. 1100, Salt Lake City, UT, 84112, USA.
Jonathan R GenzenUniversity of Utah Health, Department of Pathology, 15 N Medical Dr. East, Ste. 1100, Salt Lake City, UT, 84112, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Lipoprotein(a) [Lp(a)] is associated with increased risk of atherosclerotic cardiovascular disease. Lp(a) is commonly measured using latex-enhanced immunoassays, which are susceptible to optical, reagent, and matrix interferences. To resolve sporadic, discrepant results (i.e., outliers) observed in testing for Lp(a), the following analyses and experiments were performed. Design and methods: A dataset from a sampling period in which duplicate Lp(a) testing was performed on clinical specimens [Roche Tina-quant Lp(a) Gen.2 assay on c503 (Roche) instruments] was retrieved. Additional Lp(a) experiments included evaluation of the Roche assay on c503 instruments and Randox and Diazyme Lp(a) assays on both c503 and AU5800 (Beckman Coulter) instruments. Outliers were defined based on the average of original and repeat results: absolute differences of greater than or equal to ± 6 mg/dL (±15 nmol/L) for averages < 30 mg/dL (<75 nmol/L), or percent differences of ≥ 20% for averages ≥ 30 mg/dL (≥75 nmol/L). Replicate pairs where one or both results were outside the analytical measuring range (AMR) were excluded. Results: Of 26,637 specimens for which duplicate results were extracted, 20,832 (78.2%) had both original and repeat results within the AMR. 0.2% of these pairs (n = 49) were classified as outliers. Clinically, discrepancies were resolved by additional replicate testing. Assay optimization using Diazyme reagent was conducted to ensure thorough onboard specimen pipetting and sample/reaction mixing and washing, yielding decreases in the number of outliers. Conclusions: Immunoturbidimetric Lp(a) assays are subject to outliers that are minimized with optimization of reagent/sample mixing and wash steps.

Indexed as

Analytical variabilityApolipoprotein(a)Apolipoprotein B-100Atherosclerotic cardiovascular diseaseBiological variabilityLipoprotein(a)Total allowable error

Identifiers

PMID42871872
PMCPMC13659681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.